Natco Pharma shares climbed over 11% on February 16 after receiving approval to launch Semaglutide in India. Semaglutide is used to manage chronic weight and treat type-2 diabetes.
"Natco Pharma Limited received approval for Semaglutide from CDSCO to manufacture and market generic Semaglutide Injection in India. Natco will launch the product in the India market in March 2026. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise," said the firm in a stock exchange filing on February 14.
At 11 am on February 16, Natco Pharma shares were trading 11.6% higher at Rs 919.3 apiece.
Natco Pharma on February 12 said its consolidated net profit increased by14 per cent year on year to Rs 151 crore for the third quarter ended December 31, 2025.
The drug firm reported a net profit of Rs 132 crore for the October-December quarter of the last fiscal.
Revenue from operations rose to Rs 647 crore for the period under review as compared with Rs 475 crore in the year-ago period, Natco Pharma said in a regulatory filing.
The company said its board has declared a third interim dividend of Rs 1.5 per share for the financial year 2025-26.
The board also approved re-appointment of Venkaiah Chowdary Nannapaneni as Chairman and MD for a period of one year with effect from April 1, 2026.
The board also approved to incorporate a wholly-owned subsidiary in Chile with an investment of up to $300,000.
On February 16, among the sectoral indices, Nifty Pharma rose nearly 1%. A nearly 6% rise in shares of JB Chemicals & Pharmaceuticals supported Nifty Pharma.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
